Skip to content

AMAG closes licensing agreement for menopause med

April 8, 2017

AMAG Pharmaceuticals Inc. AMAG, +2.26% stock surged 4.4% in premarket trade Tuesday after the company said a previously-announced U.S. licensing agreement with Endoceutics Inc. for a menopause drug has closed. The drug, Intrarosa, is a steroid hormone intended for women in menopause experiencing moderate to severe pain during intercourse, which could affect 14 million to 25 million women, according to AMAG Pharmaceuticals. The drug is the only medication for the condition that doesn’t have a safety warning on its label, AMAG Pharmaceuticals said. At least half of patients with symptoms of the condition have unmet treatment need, the company said. Intrarosa was approved in November of last year and the licensing deal was first announced February 14, with an expected U.S. launch in mid-2017. AMAG Pharmaceuticals plans to pay $50 million to Endoceutics upon closing, according to its 10-K, along with common stock, up to $10 million upon delivery of launch quantities of the drug, $10 million a year from the close, tiered royalties and potential sales milestone payments. Privately-held Endoceutics Inc. and AMAG Pharmaceuticals plan to also develop the drug for female sexual dysfunction in post-menopausal women. AMAG Pharmaceuticals shares have plummeted 35.1% over the last three months, compared with a 3.9% rise in the S&P 500 SPX, -0.08%


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: